Carotid artery stenting performed by credentialed operators in the CREST-2 Registry achieved a 30-day stroke and death rate of 2.0% overall (1.4% asymptomatic, 2.8% symptomatic).
Observational (n=2,141)
Yes
Does carotid artery stenting achieve low periprocedural stroke and death rates in patients with asymptomatic or symptomatic carotid stenosis?
Carotid artery stenting performed by credentialed operators in a national registry achieved very low 30-day periprocedural stroke and death rates (2.0% overall).
BACKGROUND The CREST-2 Registry (C2R) was approved by National Institute of Neurological Disorders and Stroke-National Institutes of Health in September 2014 with Centers for Medicare 1,180 (55%) were for asymptomatic disease, and 961 (45%) were for symptomatic disease. All U.S. Food and Drug Administration-approved stents and embolic protection devices were represented. The 30-day rate of S/D was 1.4% for asymptomatic, 2.8% for symptomatic, and 2.0% for all patients. CONCLUSIONS C2R is the first national registry for CAS cosponsored by federal and industry partners. CAS was performed by experienced operators using appropriate patient selection and optimal technique. In that setting, a broad group of interventionists achieved very low periprocedural S/D rates for asymptomatic and symptomatic patients.
“It is reassuring that when the trial results come out we will be dealing with probably the best possible transfemoral stenting outcomes that can be achieved.”
Lal et al. (Sun,) conducted a observational in Asymptomatic and symptomatic carotid stenosis (n=2,141). Carotid artery stenting (CAS) was evaluated on Composite of stroke and death (S/D) in the 30-day periprocedural period. Carotid artery stenting performed by credentialed operators in the CREST-2 Registry achieved a 30-day stroke and death rate of 2.0% overall (1.4% asymptomatic, 2.8% symptomatic).